<<

. 2
( 2 .)



I?ae?auaiea ea?aiea – 6 iaoeaioia: ionoonoaea yooaeoa – 1,
oiene?iinou – 1
14 .
• ACR20– 6 iaoeaioia
• ACR50–5 iaoeaioia
• ACR70–3 iaoeaioa
Provenzano [55] Ioe?uoia, 12 iaoeaioia 26 iaa., 5 ia/ea
26 .
• ACR20–12 iaoeaioia
• ACR50–6 iaoeaioia
• ACR70–4 iaoeaioa
ACR20 – 58% eioeeeneiaa vs 11% ieaoaai (p<0,001)
PsACR– 77% eiooeeeneiaa vs 27% ieaoaai (p<0,001)
?EE (III oaca)
Antoni [57] 14 iaa., 5 ia/ea PASI 75%: 63,9 eioeeeneiaa vs 2,3 (p<0,001)
200 iaoeaioia
Nie?aiea ?enea iaoeaioia n aaeoeeeoii (p<0,001) e yioaciiaoe?
yie (p<0,016)


530 13, 8, 2005
eOCaAieaeEau
losing spondilitis. Ann Rheum Dis 2005; 64: 229–234. 64. Kruithof E, Kestelyn P, Elewaut C et al. Successful use of infliximab in a patient with treatment resistant spondy-

29. Nikas SN, Alamanos Y, Voulgari P, et al. Infliximab therapy in ankilosing spondilitis: an observational study, Ann Rheum loarthropathy related uveitis. Ann Rheum Dis 2002; 61:470

Dis 2005. 65. Fries W, Giofre MR, Catanoso M, Lo GR. Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with
30. van der Bosch F, Kruthof E, Baeten D, et al. Randomized double–blind comparison of chimeric monoclonal antibody to infliximab. Am J Gastroenterol 2002; 97:499–500.

tumor necrosis factor alpha (infliximab) versus placebo in active spondyloartghropathy. Arthritis Rheum 2002; 46: 755–765. 66. Martinez–Gonzalez O, Cantero–Hinojosa J, Paule–Sastre P, Gomez–Magan JC, Salvatierra– Rios D: Intestinal permeabil-

31. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondilitis. ity in patients with ankylosing spondylitis and their healthy relatives. Br J Rheumatol 1994; 33: 644–7.

Results of a randomized, placebo controlled trial (ASSERT). Arthritis Rhum 2005; 52: 582–591. 67. Orchard TR, Wordworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: Their articular distribu-

32. Brandt J, Listing J, Krause A, Gromnica–Ihle E, Kellner H, Schneider M, et al. Socioeconomic consequences for patients tion and natural history. Gut 1998; 42: 387–91.

with active ankylosing spondylitis treated for two years with infliximab in a clinical trial [abstract]. Ann Rheum Dis 2003; 62 68. Salvarani C, Fornaciari G, Beltrami M, Macchioni PL: Musculoskeletal manifestations in inflammatory bowel disease. Eur

(Suppl. 1). Abstract FRI0201 J Int Med 2000; 11: 210–4.
33. Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylos- 69. Targan SR, Hanauer SB, van Deventer SJH, et al: A short–term study of chimeric monoclonal antibody cA2 to tumor

ing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum necrosis factor alpha for Crohn’s Disease. Crohn’s Disease cA2 Study Group. N Engl L Med 1997; 337: 1029–35.

2003; 48:1126–36. 70. Present DH, Rutgeerts P, Targan S, et al: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Eng

34. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long–term efficacy of infliximab in Crohn`s dis- J Med 1999; 340: 398–405.
ease. New Engl J Med 2003; 348: 601–618. 71. D’Haens G, van Deventer S, van Hogenaz R, et al. Endoscopic and histological healing with infliximab anti–TNF antibod-

35. Baraliakos X, Listing J, Brand J, et al. Clinical response to discontinuation of anti–TNF therapy in patients with ankylos- ies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999; 116: 1029–34.

ing spondilitis after 3 years of continuous treatment with infliximab. Artritis ResTherapy 2005; 7 R439–R444. 72. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised

36. Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ 3rd. Fracture risk inpatients with ankylosing trial. Lancet 2002; 359: 1541–9.
spondylitis: a population based study. J Rheumatol 1994; 21:1877–82. 73. Arnott IDR, McDonald D, Williams A, Gosh S. Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience.

37. Bessant R, Keat J. Audit of the diagnosis, assessment, and treatment of osteoporosis in patients with ankylosing Aliment Pharmacol Ther 2001; 15: 1639–46

spondylitis. J Rheumatol 2003; 30:779–82. 74. van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H: Crohn’s disease associated with spondyloarthropathy:

38. Mitra D, Elvins DM, Speden DJ, Collins AJ. The prevalence of vertebral fractures in mild ankylosing spondylitis and their effect of TNF–alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821–2.

relationship to bone mineral density. Rheumatology 2000; 39:85–9. 75. Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, Schreiber S, Improvement of arthritis and arthral-
39. Allai F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with gia after treatment with Infliximab (Remicade) in a German prospective, open–lable, multicenter trial in refractory Crohn’s

spondyloarthropathy treated with anti–tumor necrosis factor alpha. Ann Rheum Dis 2003; 62:347–9. disease. Am J Gastroenterol 2002; 97:2688–90.

40. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM. Repeated infusions of infliximab, 76. Gernerini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn`s disease: an open study

a chimeric SP, Emery P. Bone mineral density improvement in spondyloarthropathy: one year follow up. Ann Rheum Dis on the efficacy in inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis on line
2003; 62:1020–1. 2005.

41. Fernandez–real JM, Rixart W. Insulin Resistance and chronic cardiovascular inflammatory syndrome. Endocrinol Re 77. Baeten D, van Damme N, van den Bosch F, et al. Impaired Th1 cytokine production in spondiloarthropathy is restored by

2003; 278–303. anti–TNF alpha. Ann Rheum Dis 2001; 60: 755–765

42. Kiortsis D, Mavridis AK, Vasakos S et al. Effect of infliximab treatment on insulin resistance in patients with rheumatoid 78. Zou JX, Rudmaleit M, Brandt J, et al. Down–regulation of non–specific and antigen–specific T cell cytokine response in

arthritis and ankylosing spondilitis. ankylosing spondilitis during treatment with infliximab. Arthritis Rheum 2003; 48: 780–790.
43. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti–tumor necrosis factor agents 79. Baeten D, Kruithof E, Van den Bosch F et al. Immunomodulatory effects of anti–tumor necrosis factor alpha therapy on

in patients with ankylosing spondilitis. Ann Rheum Dis 2003; 62: 817–824 synovium in spondylarthropathy. Histologic findings in eight patients from an open–label pilot study. Arthritis Rheum 2001;

44. Paul S, Keat A. Assesment of patients with spondyloarthrpathies for treatment with tumor necrosis factor blockade. 44:186–95.

Rheumatology 2005; 44: 17–23 80. Canetr JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti–tumor necrosis factor alpha therapy with inflix-
45. van der Heijde D, Dougados M, Davis J, et al. Assessment in ankylosing spondilitis international working imab in psoriatic arthritis. Arthritis Rheum 2004; 50: 1636–1641.

group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondilitis. Arthritis 81. Stone MA, Payne U, Pacheco–Tena C, Inman RD. Cytokine correlates of clinical response patterns to infliximab treatment

Rheum 2005; 52: 386–394 of ankylosing spondilitis. Ann Rheum Dis 2004; 63: 84–87.

46. cOOIO‚ Oa. e?EIAIAIEA EIUIEIOEI· (IOIOIIOII?I?A IUEUAI I UIUO?U IAI?OA OOU?OIE –?) ‚ ?A‚IUOIO- 82. Rudwaleit M, Listing J, Brandt J, et al. Prediction on a major clinical response (BASDAI 50) to TNF–? blokers in ankilo-
„EE: IO‚?A UIU? E EAE. eaU 2004;20; 1123–1127. sing spondilitis? Ann Rheum Dis 2004; 63: 665–670.

47. Gladman DD, Stafford–Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological 83. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Is there a role of MRI in predicting the clinical response to TNF–alpha

progression in psoriatic arthritis. J Rheumatol 1990; 17:809–12. blockers in ankylosing spondilitis? Ann Rheum Dis 2003; 62: 97.

48. McHugh NJ, Balakrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis. Rheumatology 2003; 84. D’Agostino MA, Breban M, Said–Nahal R, Dougados M: Refractory inflammatory heel pain in spondyloarthropathy: a sig-

42:778–83. nificant response to infliximab documented by ultrasound. Arthritis Rheum 2002, 46:840–841

49. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy 85. Braun J, Sieper J: Refractory inflammatory heel pain in spondyloarthropathy: a significant response to infliximab docu-
for plaque–type psoriasis: a randomised trial. Lancet 2001;357: 1842–7. mented by ultrasound. Arthritis Rheum 2002, 46:841–842

50. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler GS, et al. Treatment of psoriatic arthritis with antitumor 86. Olivieri I, Padula A, Ciancio G, et al. Succesful treatment of SAPHO syndrome with infliximab: report pf two cases. Ann.
necrosis factor–alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol Rheum Dis 2002; 61: 375–376

2001:144:587–9. 87. Kellner H, Kroetz M, Schattenkitchner M, Kellner W. Succesful therapy of sacroiliitis in AS patients by intraarticular injec-

51. Gottlieb AB, Antoni CE. Treating psoriatic arthritis: how effective are TNF antagonists? Arthritis Res Ther 2004; 6 (Suppl tion of infliximab. Arthritis Rheum 2002; 46: (Suppl): 431

2): S31–S35.

52. Antoni C, Dechant C, Hanns–Martin Lorenz PD et al. Open–label study of infliximab treatment for psoriatic arthritis: clin-

ical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47:506–12.

53. Salvarani C, Cantini F, Olivieri I et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003; 49:541–5.
54. Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a

12 month observational study of 16 patients. Ann Rheum Dis 2004; 63:156–61.
55. Provenzano G, Termini A, le Moli C, Rinadi F. Efficacy of infliximab in psoriatic arthritis resistant to treatment with dis-

ease modifying antirheumatic drugs: an open pilot study. Ann Rheum Dis 2003; 62: 680–681

56. Antoni A, Ogilvie A, Lueftl M et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis

Rheum 2002; 46 (Suppl. 9):S381.

57. Antoni C, Krueger G, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the

IMPACT 2 trial. Ann Rheum Dis 2005 on line.
58. Kyle S, Chandler D, Griffiths CEM, et al. Guideline for anti–TNF–? therapy in psoriatic arthritis. Rheumatology 2005 on

line..

59. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short– term treatment of severe undifferentiated spondy-
loarthropathy with the anti–tumor necrosis factor– monoclonal antibody infliximab. J Rheumatol 2002; 29:118–22.

60. Oili KS, Niinisalo H, Korpilahde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scand J Rheumatol 2003;

32: 122–4.

61. Gaylis N. Infliximab in the treatment of an HIV positive patients with Reiter`s syndrome. J Rheumatol 2003; 30: 407–411.

62. Stamp LK, O`Donnell JL. HLA–B–27 associated spondyloarthropathy, vasculitis, and amyloid enteropathy; response to

unfliximab. J Rheumatol 2005; 32: 383–385

63. El–Shabrawi Y, Hermann J. Anti–tumor necrosis factor–alpha therapy with infliximab as an alternative to corticosteroids
in the treatment of human leukocyte antigen B27–associated acute anterior uveitis. Ophthalmology 2002;109: 2342–6.



531

13, 8, 2005

<<

. 2
( 2 .)